Ishtiaq Rehman

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. pmc iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer
    Ishtiaq Rehman
    Department of Human Metabolism, The Medical School, The Mellanby Centre for Bone Research, University of Sheffield, Sheffield, United Kingdom
    PLoS ONE 7:e30885. 2012
  2. ncbi request reprint DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer
    Ishtiaq Rehman
    Academic Urology Unit, Division of Clinical Sciences South, University of Sheffield, Sheffield, UK
    Prostate 67:341-7. 2007
  3. ncbi request reprint Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer
    Ishtiaq Rehman
    Academic Urology Unit, Division of Clinical Sciences South, University of Sheffield, United Kingdom, and Service d Urologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Prostate 65:322-30. 2005
  4. pmc S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors
    I Rehman
    Academic Urology Unit, Division of Clinical Sciences South, University of Sheffield, Floor K, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK
    Br J Cancer 91:739-44. 2004
  5. ncbi request reprint Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma
    James W F Catto
    Academic Urology Unit, K Floor, Royal Hallamshire Hospital, Glossop Rd, Sheffield, S10 2JF United Kingdom
    J Clin Oncol 23:2903-10. 2005
  6. ncbi request reprint Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study
    Adam Glen
    Department of Human Metabolism, The Mellanby Centre for Bone Research, University of Sheffield Medical School, Sheffield, UK
    Prostate 70:1313-32. 2010
  7. ncbi request reprint Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A
    Aaron Leiblich
    Section of Oncology, Academic Urology Unit, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK
    Prostate 67:1761-9. 2007
  8. ncbi request reprint Promoter hypermethylation in circulating blood cells identifies prostate cancer progression
    Morgan Roupret
    Institute for Cancer Studies, University of Sheffield, Royal Hallamshire Hospital, Sheffield, United Kingdom
    Int J Cancer 122:952-6. 2008
  9. ncbi request reprint iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression
    Adam Glen
    Academic Urology Unit, Section of Oncology, University of Sheffield, Floor K, Royal Hallamshire Hospital, Glossop Road, Sheffield, S10 2JF, UK
    J Proteome Res 7:897-907. 2008
  10. ncbi request reprint Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions
    Ishtiaq Rehman
    Academic Urology Unit, Division of Clinical Sciences South, University of Sheffield, UK
    Hum Pathol 35:1385-91. 2004

Detail Information

Publications28

  1. pmc iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer
    Ishtiaq Rehman
    Department of Human Metabolism, The Medical School, The Mellanby Centre for Bone Research, University of Sheffield, Sheffield, United Kingdom
    PLoS ONE 7:e30885. 2012
    ..Our proteomic approach has identified leads for potentially useful serum biomarkers associated with the metastatic progression of prostate cancer. The panels identified, including eEF1A1 warrant further investigation and validation...
  2. ncbi request reprint DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer
    Ishtiaq Rehman
    Academic Urology Unit, Division of Clinical Sciences South, University of Sheffield, Sheffield, UK
    Prostate 67:341-7. 2007
    ..The role of DNA methylation in the transcriptional regulation of S100A4 is unknown in human prostate cancer...
  3. ncbi request reprint Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer
    Ishtiaq Rehman
    Academic Urology Unit, Division of Clinical Sciences South, University of Sheffield, United Kingdom, and Service d Urologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Prostate 65:322-30. 2005
    ..S100A6 and S100A2 are members of the S100 family of calcium binding proteins, which are down regulated in prostate cancer, however the molecular mechanism(s) underlying their loss of expression is unknown...
  4. pmc S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors
    I Rehman
    Academic Urology Unit, Division of Clinical Sciences South, University of Sheffield, Floor K, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK
    Br J Cancer 91:739-44. 2004
    ..The finding of intense S100A6 expression in the basal cells of benign glands but loss of expression in cancer could be useful as a novel diagnostic marker for prostate cancer...
  5. ncbi request reprint Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma
    James W F Catto
    Academic Urology Unit, K Floor, Royal Hallamshire Hospital, Glossop Rd, Sheffield, S10 2JF United Kingdom
    J Clin Oncol 23:2903-10. 2005
    ..Here we investigate the extent of promoter hypermethylation in TCC throughout the urinary tract...
  6. ncbi request reprint Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study
    Adam Glen
    Department of Human Metabolism, The Mellanby Centre for Bone Research, University of Sheffield Medical School, Sheffield, UK
    Prostate 70:1313-32. 2010
    ..Due to the heterogeneity in the biological behavior of prostate cancer, biomarkers that can reliably distinguish indolent from aggressive disease are urgently needed to inform treatment choices...
  7. ncbi request reprint Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A
    Aaron Leiblich
    Section of Oncology, Academic Urology Unit, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK
    Prostate 67:1761-9. 2007
    ..To identify novel candidates associated with metastatic progression, we compared the proteomic profiles of LNCaP (lymph-node metastatic, androgen-dependant) and PC-3 (bone metastatic, androgen-independent), human prostate cancer cells...
  8. ncbi request reprint Promoter hypermethylation in circulating blood cells identifies prostate cancer progression
    Morgan Roupret
    Institute for Cancer Studies, University of Sheffield, Royal Hallamshire Hospital, Sheffield, United Kingdom
    Int J Cancer 122:952-6. 2008
    ..The extent of this hypermethylation increases during disease progression and can be used to identify the extent and duration of treatment response in prostate cancer...
  9. ncbi request reprint iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression
    Adam Glen
    Academic Urology Unit, Section of Oncology, University of Sheffield, Floor K, Royal Hallamshire Hospital, Glossop Road, Sheffield, S10 2JF, UK
    J Proteome Res 7:897-907. 2008
    ..0005, Mann-Whitney U). Our study is the first to report the application of iTRAQ technology and its potential for the global proteomic profiling of prostate cancer cells, including the identification of absent protein expression...
  10. ncbi request reprint Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions
    Ishtiaq Rehman
    Academic Urology Unit, Division of Clinical Sciences South, University of Sheffield, UK
    Hum Pathol 35:1385-91. 2004
    ..Our finding of frequent dysregulated expression of S100A11 in cancer and precursor lesions, together with an association with high histological stage, suggests that S100A11 may be involved in prostate cancer development and progression...
  11. ncbi request reprint Promoter hypermethylation identifies progression risk in bladder cancer
    David R Yates
    Institute of Cancer Studies, Academic Urology Unit, Academic Pathology Unit, and Department of Automatic Control and Systems Engineering, The University of Sheffield, Sheffield, United Kingdom
    Clin Cancer Res 13:2046-53. 2007
    ..Here, we investigate a panel of methylated loci in a prospectively collected cohort of bladder tumors to determine whether hypermethylation has a useful role in the management of patients with bladder cancer...
  12. ncbi request reprint Clinically localised prostate cancer is microsatellite stable
    Abdel Rahmene Azzouzi
    Service d Urologie, CHU d Angers, Centre de Recherche pour les Pathologies Protatiques, Universite Paris VII, Paris, France, and Department of Pathology, Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 99:1031-5. 2007
    ..To determine the frequency of microsatellite instability (MSI) change with mono-, di- and tetranucleotide markers in clinically localized prostate cancer, and to correlate those markers with clinical and pathological variables...
  13. pmc Distinct microRNA alterations characterize high- and low-grade bladder cancer
    James W F Catto
    Academic Urology Unit, University of Sheffield, Sheffield, United Kingdom
    Cancer Res 69:8472-81. 2009
    ..In conclusion, distinct microRNA alterations characterize UCC and target genes in a pathway-specific manner. These data reveal new insights into the disease biology and have implications regarding tumor diagnosis, prognosis and therapy...
  14. ncbi request reprint Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer
    Colby L Eaton
    School of Medicine, University of Sheffield, Sheffield, UK
    Prostate 70:875-82. 2010
    ..In this study we have, for the first time, assessed matched primary and bone marrow biopsies from prostate cancer patients for the distribution of cells carrying these and a number of other putative stem cell markers...
  15. ncbi request reprint The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression
    James W F Catto
    Academic Urology Unit, University of Sheffield, Sheffield, United Kingdom
    Eur Urol 57:398-406. 2010
    ..Gene expression microarrays can reveal insights into disease biology and identify novel biomarkers. However, these experiments produce large datasets that are difficult to interpret...
  16. ncbi request reprint Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage
    Morgan Roupret
    Institute for Cancer Studies and Academic Urology Unit, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK
    Clin Cancer Res 13:1720-5. 2007
    ..Many patients require repeat prostate biopsies to diagnose the disease. We investigated whether aberrant promoter hypermethylation in prostatic fluid could reliably detect prostate cancer...
  17. ncbi request reprint Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance
    James W F Catto
    Academic Urology Unit, University of Sheffield, Sheffield, United Kingdom
    J Urol 175:2323-30. 2006
    ..Tumors with high MSI have numerous DNA mutations, of which many provide no selection benefit. While these tumors represent an ideal model for studying UC clonality, their low frequency has prevented their previous investigation...
  18. ncbi request reprint The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers
    Elizabeth A Waterman
    Academic Unit of Urology, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
    Int J Cancer 121:1958-66. 2007
    ..We conclude that care should be exercised using this antibody for immunohistochemistry studies, without additional in situ hybridisation, or parallel use of other OPG-specific antibodies...
  19. ncbi request reprint Behavior of urothelial carcinoma with respect to anatomical location
    J W F Catto
    Academic Urology Unit, University of Sheffield, Sheffield, United Kingdom
    J Urol 177:1715-20. 2007
    ..Observational studies conflict as to the significance of anatomical location on the behavior of urothelial carcinoma. We compared the biological outcome in a large series of urothelial carcinoma with respect to anatomical location...
  20. ncbi request reprint Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers
    S S Cross
    Academic Unit of Pathology, Division of Genomic Medicine, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
    Histopathology 46:256-69. 2005
    ..S100A6, S100A8, S100A9 and S100A11 have all been suggested to have potential roles in carcinogenesis and tumour progression but their expression has not been described in a wide range of human tissues and tumours...
  21. ncbi request reprint Distinct patterns of microsatellite instability are seen in tumours of the urinary tract
    James W F Catto
    The Institute for Cancer Studies, University of Sheffield, UK
    Oncogene 22:8699-706. 2003
    ..In addition, we have confirmed that MSI and EMAST are discrete forms of MSI, and that the presence of EMAST does not affect tumour phenotype...
  22. ncbi request reprint Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma
    D Dhawan
    Academic Urology Unit, University of Sheffield, and Department of Urology, Royal Hallamshire Hospital, UK
    J Pathol 209:336-43. 2006
    ..03). Promoter methylation occurs early in the urothelial carcinogenic pathway and appears to be a good biomarker of the invasive urothelial carcinoma phenotype...
  23. ncbi request reprint Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer
    A Leiblich
    Academic Urology Unit, Division of Clinical Sciences South, University of Sheffield, UK
    Oncogene 25:2953-60. 2006
    ..001). Absent LDHB expression was also seen in 7/7 (100%) cases of metastatic cancer in bone. Our data are the first to show loss of LDHB expression in prostate cancer, the mechanism of which appears to involve promoter hypermethylation...
  24. pmc Lactate dehydrogenase-B is silenced by promoter methylation in a high frequency of human breast cancers
    Nicola J Brown
    Department of Oncology, The Medical School, University of Sheffield, Sheffield, United Kingdom
    PLoS ONE 8:e57697. 2013
    ..We aimed to elucidate the mechanisms contributing to the Warburg effect in human breast cancer...
  25. doi request reprint iTRAQ underestimation in simple and complex mixtures: "the good, the bad and the ugly"
    Saw Yen Ow
    ChELSI Institute, Chemical and Process Engineering, University of Sheffield, Mappin Street, S1 3JD Sheffield, United Kingdom
    J Proteome Res 8:5347-55. 2009
    ..In light of our results, we propose a list of advice for iTRAQ data analysis that could routinely ameliorate quantitative interpretation of proteomic data sets...
  26. ncbi request reprint Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study
    I Rehman
    Academic Urology Unit, Division of Clinical Sciences South, University of Sheffield, Sheffield, United Kingdom
    Urology 64:1238-43. 2004
    ..Serum prostate-specific antigen measurements are widely used for the early detection of prostate cancer but lack specificity, thus warranting the search for additional biomarkers...
  27. ncbi request reprint Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls
    D R Yates
    Institute for Cancer Studies, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK
    Oncogene 25:1984-8. 2006
    ..The frequency and extent of methylation appears to increase with age and malignancy. The lack of tumour specificity suggests that further investigation is required before this test is introduced into clinical practice...
  28. ncbi request reprint Methylation of the O6-methylguanine-DNA methyltransferase promoter suppresses expression in mouse skin tumors and varies with the tumor induction protocol
    Rana Abdel-Fattah
    Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Int J Cancer 118:527-31. 2006
    ....